Company news
Duality Biotherapeutics, Inc. news in 2025
Duality Biotherapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
July 21, 2025
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
July 8, 2025
Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting
June 4, 2025
FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
May 22, 2025